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Abstract
Background: We assessed the impact of donor type in acute
myeloid leukemia (AML) patients transplanted with 2 Gy total
body irradiation (TBI)-based nonmyeloablative conditioning
regimen.
Experimental Design: Data from 1,715 adult patients,
with AML in CR1 or CR2 were included in this retrospective
survey.
Results: Donors consisted either of HLA-matched sibling
donors (MSD, n ¼ 701), 10/10 HLA-matched unrelated donors
(MUD, n¼ 611), HLA-haploidentical donors (haplo, n¼ 112) or
single or double umbilical cord bloods (CBT, n ¼ 291). Chronic
graft-versus-host disease (GVHD)was less frequent in CBT (28%)
and inhaplo (30%)patients than inMSD(50%) andMUD(51%)
recipients (P < 0.001). Two-year incidence of relapse was 32%,
30%, 34%, and 34% in MSD, MUD, CBT and haplo patients,
respectively (P ¼ 0.7). Two-year overall (OS) and GVHD-free
relapse-free survival (GRFS) were 59% and 29% inMSD patients,
56% and 39% in CBT recipients, 53% and 23% in MUD recipi-
ents, and 43% and 37% in haplo patients, respectively. In mul-
tivariate analyses, MUD patients had lower GRFS than MSD
patients beyond day 100 (HR 1.3, P ¼ 0.001) while CBT was
associated with a better GRFS thanMSDbeyond day 100 (HR 0.6,
P ¼ 0.002).
Conclusions: In this large cohort of AML patients transplanted
following low-dose TBI-based conditioning, the relapse incidence
was not affected by donor type suggesting that the intensity of
GVL effects might be comparable with these four transplant
approaches. Furthermore, CBT was associated with better GRFS
beyond day 100 than MSD while the opposite was observed for
MUD. Clin Cancer Res; 1–10. 2018 AACR.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HCT)
is increasingly used in older patients with acutemyeloid leukemia
(AML; refs. 1–3).On the basis of discoveries in a preclinical canine
model of transplantation (4), a truly nonmyeloablative condi-
tioning regimen consisting of 2 Gy total body irradiation (TBI)
with or without added ﬂudarabine has been developed by the
Seattle team (5–8). This conditioning allowed successful engraft-
ment with minimal toxicities with either HLA-identical sibling or
HLA-matchedunrelateddonors (5, 8–14). Identical backbonehas
later been adapted by adding pretransplant or pre- and posttrans-
plant cyclophosphamide (Cy) to allow successful umbilical cord
blood (CBT) or HLA-haploidentical (haplo) transplantation,
respectively (15–19).
Low-dose TBI-based nonmyeloablative allo-HCT relies
nearly exclusively on immune-mediated graft-versus-leuke-
mia (GvL) effects for tumor eradication (20–23). As GvL
effects are in a large part directed against genetic disparities
between the patient and his donor, one could speculate that
increasing genetic disparities between the donor and the
recipient might result in higher GvL effects (24, 25). Here,
we assessed the impact of donor type on transplantation
outcomes in a large cohort of AML patients transplanted in
CR with low-dose TBI-based nonmyeloablative conditioning
regimens.
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Patients and Methods
Data collection
This is a retrospective, multicenter registry-based study
performed by the Acute Leukemia Working Party (ALWP) of
the European society for Blood and Marrow Transplantation
(EBMT). EBMT registry is a voluntary working group of more
than 500 transplant centers, participants of which are required
once a year to report all consecutive stem cell transplantations
and follow-up. Audits are routinely performed to determine the
accuracy of the data. Inclusion criteria were adult ( 18 years)
patients, de novo or secondary AML in ﬁrst (CR1) or second
(CR2) complete remission, transplantation between 2004 and
2016, conditioning with ﬂudarabine þ 2 Gy TBI with or
without pre- or posttransplant cyclophosphamide, no in vitro
or in vivo (other than posttransplant Cy, i.e., no ATG and
no alemtuzumab) T-cell depletion of the graft, and either an
HLA-matched sibling donor (MSD), a 10/10 HLA-matched
unrelated donor (MUD), an HLA-haplo-identical donor
(Haplo), or a single or double umbilical cord blood (CBT).
For CBT, HLA-compatibility requirements followed the current
practice of antigen level typing for HLA-A and -B and allele-
level typing of HLA-DRB1. CB units were 4–6/6 HLA-A, -B, and
-DRB1 matched to the recipient in all patients and to the other
unit in case of double CBT in most patients (26, 27). HLA
disparities between each unit and the recipient and between the
two units were not necessarily at the same loci. The choice
between single or double CBT was done according to transplant
center policy (26, 28). Generally, double CBT was performed
when a single unit with adequate cell dose was not available.
Grading of acute and chronic GVHD was performed using
established criteria (29).
For the purpose of this study, all necessary data were collected
according to EBMT guidelines.
Ethics approval and consent to participate
The scientiﬁc board of the ALWP of EBMT approved this study.
Statistical analyses
Data from all patients meeting the inclusion/exclusion
criteria were included in the analyses. We did not censor
patients who did not engraft. Furthermore, as the comparison
of donor type was done in an intent-to-treat principle, we did
not censor patients at time of second allo-HCT. The latter was
given in 52 MSD, 27 MUD, 5 haplo, and 20 CBT patients,
respectively. Patient, disease, and transplant-related character-
istics for the 4 cohorts (MSD/UD/CBT/Haplo) were compared
by using x2 statistics for categorical variables and the Kruskal–
Wallis test for continuous variables. Start time was date of
transplant for all endpoints. As follow-up duration varied
signiﬁcantly between the 4 groups, all survival times were
censored 2 years after transplantation. Measured outcomes
were leukemia-free survival (LFS), relapse incidence (RI), non-
relapse mortality (NRM), overall survival (OS), acute graft-
versus-host disease (aGVHD), chronic graft-versus-host-disease
(cGVHD), and GVHD and relapse-free survival (GRFS). LFS
was deﬁned as survival with no evidence of relapse or pro-
gression. Relapse was deﬁned as the presence of 5% bone
marrow blasts and/or reappearance of the underlying disease.
NRM was deﬁned as death without evidence of relapse or
progression. OS was deﬁned as the time from alloSCT to
death, regardless of the cause. GRFS was deﬁned as being
alive with neither grade III–IV acute GVHD, extensive chronic
GVHD nor disease relapse (30). Neutrophil engraftment was
deﬁned as ﬁrst of 3 consecutive days with a neutrophil count
of at least 0.5  109/L.
Cumulative incidences were used to estimate the endpoints of
NRM, RI, engraftment, and acute and chronic GVHD to accom-
modate for competing risks. To study acute and chronic GVHD,
we considered relapse and death to be competing events. Prob-
abilities of OS, LFS, and GRFS were calculated using the Kaplan–
Meier method. Univariate analyses were done using the Gray test
for cumulative incidence functions and the log rank test for OS,
GRFS, and LFS.
Associations between donor type (MSD, MUD, haplo, CBT)
and transplantation outcomes were evaluated in multivariable
analyses, using Cox proportional hazards. All variables differing
signiﬁcantly between the 4 groups or factors known to inﬂuence
outcomes were included in the Cox model. Variables introduced
in the Cox models included recipient age (in decades), year of
transplantation, disease status at allo-HCT, primary or secondary
AML, cytogenetic risk, female donor to male recipient or not, and
patient and donor CMV serostatus. To test for a centre effect, we
introduced a random effect or frailty for each center into the
model (31). Proportional hazards assumptions were checked
systematically for all proposed models using the Grambsch–
Therneau residual-based test. Proportionality assumption was
signiﬁcantly violated when studying GRFS, relapse, and nonre-
lapse mortality. We thus split the follow-up of these endpoints at
day 100. This cut-off point was chosen based on a clinical
rationale, after occurrence of acute GVHD and before occurrence
of chronic GVHD.
All tests were two sided. The type I error rate was ﬁxed at 0.017
for determination of factors associated with time to event out-
comes after using the Bonferroni correction for three compari-
sons. Statistical analyses were performed with SPSS 24.0 (SPSS
Inc) and R 3.4.1 (https://www.R-project.org/).
Results
Patients and donors
Data from all 1,715 patients meeting the inclusion/exclusion
criteria were included in the analyses. They received grafts from
either MSD (n ¼ 701), MUD (n ¼ 611), or haplo (n ¼ 112)
donors or were given single or double CBT (n ¼ 291; Table 1).
The proportion of patients transplanted in CR1 was 86%, 80%,
66%, and 61% in MSD, MUD, haplo, and CBT groups, respec-
tively (P < 0.001). Median patient age at transplantation was
58, 62, 58, and 55 years, respectively (global P < 0.001). The
proportion of patients with secondary AML was 15%, 20%,
14%, and 18% in MSD, MUD, haplo, and CBT groups (global
Translational Relevance
Relapse incidencewas not affected by donor type suggesting
that the intensity of GVL effects is comparable with these four
transplant approaches. Further, LFS was comparable with
these four transplant approaches. Finally, GRFS beyond day
100 was better withMSD than with MUDwhile GRFS beyond
day 100 was better with CBT than with MSD.
Baron et al.
Clin Cancer Res; 2018 Clinical Cancer ResearchOF2
Research. 
on June 12, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst March 19, 2018; DOI: 10.1158/1078-0432.CCR-17-3622 
P ¼ 0.06). Median follow-up was 66, 30, 18, and 49 months,
respectively (global P < 0.001). Stem cell source was peripheral
blood stem cells (PBSC) in 98% of MSD and MUD recipients,
but 53% in haplo patients. Post grafting immunosuppression
consisted mainly on a combination of calcineurin inhibitors þ
MMF in MSD, MUD and CBT patients, while all haplo patients
received in addition posttransplant Cy for rejection/GVHD
prophylaxis. As mentioned in the Patients and Methods section
of the article, the use of ATG or alemtuzumab was an exclusion
criterion in this survey.
Engraftment and GVHD
Graft rejection occurred in 2% of each MSD and MUD reci-
pients, 5% of haplo patients, and 6% of CBT recipients (P <
0.001). Cumulative incidences of neutrophil engraftment were
98%, 98%, 95% ,and 94%, respectively (global P < 0.001). At day
30, the ﬁgures were 94%, 95%, 90%, and 80%, respectively
(global P < 0.001). Second allo-HCT as treatment of graft failure
was offered in 5 of 16MSD patients, 9 of 12MUD patients, 1 of 6
haplo patients, and 5 of 20 CBT recipients. Two-year OS in the 54
patients with graft failure was 37%.















Median patient age, y (range) 58 (18–74) 62 (18–77) 58 (19–74) 55 (18–73) <0.001 0.6 <0.001
Median follow-up, mo (range) 66 (1–155) 30 (1–132) 18 (2–95) 49 (3–152) <0.001 <0.001 0.001
Median year of Tx 2010 2012 2014 2010 <0.001 <0.001 0.1
Median time from diagnosis to Tx in CR1
patients, mo (IQR)
4.2 (3.4–5.2) 4.7 (3.7–5.9) 5.3 (4.4–7.0) 5.8 (5.1–7.2) <0.001 <0.001 <0.001
Median time from diagnosis to Tx in CR2
patients, mo (IQR)
18 (13–26) 21 (15–28) 20 (13–27) 21 (15–27) 0.3 0.5 0.13
Recipient gender M, # (%) 375 (54) 328 (54) 67 (60) 133 (46) 0.9 0.2 0.03
F donor to M recipient, # (%) 188 (27) 53 (9) 20 (18) 60 (21) <0.001 0.05 0.08
Median donor age, y (range) 55 (15–79) 30 (18–58) 34 (18–70) NA <0.001 <0.001 NA
Karnofsky performance status at Tx 0.5 0.8 0.9
<80 43 (7) 34 (6) 8 (8) 17 (7)
80 587 (93) 542 (94) 97 (92) 240 (93)
Missing 71 35 7 34
Diagnosis, # (%) 0.009 0.9 0.3
De novo AML 597 (85) 487 (80) 96 (86) 240 (82)
Secondary AML 104 (15) 124 (20) 16 (14) 51 (18)
Status at Tx, # (%) 0.002 <0.001 <0.001
CR1 606 (86) 490 (80) 74 (66) 177 (61)
CR2 95 (14) 121 (20) 38 (34) 114 (39)
Stem cell source 0.2 <0.001 NA
Bone marrow 15 (2) 11 (2) 53 (47) NA
Peripheral blood stem cells 685 (98) 600 (98) 59 (53) NA
Single CBT NA NA NA 82 (28)
Double CBT NA NA NA 209 (72)
Cytogenetics, # (%) 0.4 0.5 0.5
Good riskb 38 (8) 18 (6) 7 (9) 19 (9)
Intermediate riskc 333 (71) 204 (69) 53 (65) 146 (66)
High riskd 100 (21) 73 (25) 22 (27) 55 (25)
Not reported/failed 230 316 30 71
FLT3-ITD, # (%) 0.009 0.03 0.4
Negative 129 (68) 99 (63) 44 (83) 64 (63)
Positive 61 (32) 59 (37) 9 (17) 38 (37)
Missing 511 453 59 189
Patient CMV seropositive, # (%) 472 (68) 387 (64) 78 (70) 180 (63) 0.2 0.7 0.1
Fludarabine dose (mg/m2), # (%) NS <0.001 <0.001
90 548 (89) 516 (91) 0 1
150 65 (11) 49 (9) 94 (100) 23 (9)
200 3 (0.5) 2 (0.5) 0 221 (90)
Missing 85 44 18 46
Postgrafting immunosuppression, # (%)
CSP (or tacro) þ MMF 627 (90) 547 (90) 0 268 (92) <0.001 <0.001 <0.001
Posttransplant cyclophosphamidee 33 (4) 34 (6) 112 (100)f 3 (1)
Other 41 (6) 30 (5) 0 20 (8)
Abbreviations: #, number of patients; CBT, cord blood transplantation; CR, complete remission; CSP, cyclosporine; diagn, diagnosis; FLT3-ITD, FMS-related tyrosine
kinase 3 internal tandem duplication; IQR, interquartile ranges; M, male; MSD, HLA-matched sibling donor; MMF, mycophenolate mofetil; Tx, transplantation; UD,
unrelated donor; Y, year.
aCalculated with x2 statistics for categorical variables and Mann-Whitney test for continuous variables.
bDeﬁned as t(8;21), t(15;17), inv or del (16), or acute promyelocyticleukemia, these abnormalities only or combined with others.
cDeﬁned as all cytogenetics not belonging to the good or high risk (including trisomias).
dDeﬁned as 11q23 abnormalities, complex karyotype, abnormalities of chromosomes 5 and 7. No patient received ATG or alemtuzumab.
eWith or without added immunosuppressive drugs.
f105 patients received CSP (or tacro) þMMF, 4 patients CSP, 1 patient MMF and 2 patients other immunosuppressive drugs in addition to post-transplant
cyclophosphamide.
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Grade II–IV acute graft-versus-host disease (GVHD) was
more frequent in CBT (38%), haplo (31%), and MUD
(30%) recipients than in MSD recipients (19%; global P <
0.001; Fig. 1A). Grade III–IV acute GVHD was more frequent
in CBT (15%) than in MUD (9%), haplo (7%), or MSD (7%)
recipients (global P < 0.001). In multivariate analysis, in
comparison with MSD, CBT, and MUD were associated
with a higher incidence of grade II–IV acute GVHD while grade
III–IV acute GVHD was more frequent in CBT than in MSD
recipients (Table 2).
Chronic GVHD was less frequent in CBT (28%) and in haplo
(30%) patients than in MSD (50%) and MUD (51%) recipients
(P < 0.001; Fig. 1A). Similarly, extensive chronic GVHD was less
frequent in CBT (9%) and in haplo (11%) patients than in MSD
(31%) and MUD (34%) recipients (P < 0.001). In multivariate
analysis, in comparison withMSD recipients those given CBT had
a lower incidence of chronic and extensive chronic GVHD while
MUD had a higher incidence of chronic and extensive chronic
GVHD (Table 2). Female donor to male recipients was
also associated with a higher incidence of chronic (HR¼1.4;
95% CI, 1.1–1.7; P ¼ 0.008) and extensive chronic (HR¼1.6;
95% CI, 1.2–2.2; P ¼ 0.003) GVHD.
Relapse and NRM
Two-year incidence of relapse was 32% in MSD patients, 30%
in MUD recipients, and 34% in CBT and haplo recipients, respec-
tively (P ¼ 0.7; Fig. 1B). In multivariate analyses, there was no
impact of donor type on the risk of relapse. Factors associatedwith
higher risk of relapse included intermediate (HR¼1.5; 95%
CI, 1.0–2.1; P ¼ 0.04) or adverse cytogenetics (HR¼3.4; 95% CI,
2.3–5.1; P < 0.001) and donor CMV seropositivity (HR¼1.3; 95%
CI, 1.1–1.5; P ¼ 0.009), while female donor to male recipient
(HR¼0.7; 95% CI, 0.6–0.9; P ¼ 0.015) was associated with a
lower risk of relapse (Table 3).
Two-year incidence of nonrelapsemortality (NRM)was 13% in
MSD patients, 20% in MUD recipients, 16% in CBT recipients,
and 22% in haplo patients, respectively (P < 0.001; Fig. 1A). In
multivariate analyses, in comparison with MSD patients, each
other donor type was associated with a signiﬁcantly higher NRM
the ﬁrst 100 days after transplantation while MUD recipients had
also higher NRM beyond day 100. Furthermore, increasing age at
transplantation (per 10 year;HR¼1.4; 95%CI, 1.2–1.6;P<0.001)
and female donor to male recipients (HR¼1.7; 95% CI, 1.3–2.3;
P < 0.001) were also associated with higher NRM (Table 3).
LFS and OS
Two-year LFS was 54% in MSD patients, 50% in MUD and in
CBT recipients, and 44% in haplo patients (global P ¼ 0.14;
Fig. 1B). Factors associatedwithworse LFS inmultivariate analysis
included intermediate (HR¼1.6; 95% CI, 1.0–2.4; P ¼ 0.04) and
adverse (HR¼2.9; 95%CI, 1.8–4.5; P < 0.001) cytogenetics, while
a similar trend was observed for secondary AML (HR¼1.3; 95%
CI, 1.0–1.7; P ¼ 0.06; Table 4).
Two-year OS was 59% in MSD patients, 56% in CBT recipients
(P¼ 0.5 in comparison with MSD), 53% in MUD recipients (P¼
0.004 in comparison withMSD), and 43% in haplo patients (P¼
0.02 in comparison with MSD; Fig. 1B). In multivariate analysis
there was a suggestion of lower OS in haplo (P ¼ 0.09) than
in MSD recipients (Table 4). Factors associated with worse OS in
multivariate analysis included intermediate (HR¼1.9; 95% CI,
1.2–3.1; P ¼ 0.01) and adverse (HR¼3.4; 95% CI, 2.0–5.7;
P < 0.001) risk cytogenetics, and secondary AML (HR¼1.4;
95% CI, 1.0–1.8; P ¼ 0.04).
AML relapse, GVHD, and infections were the primary causes of
death during thewhole studyperiod for 27%, 7%, and5%ofMSD
recipients, 21%, 8%, and 7% of MUD recipients, 18%, 5%, and
12%of haplo recipients, and 28%, 8%, and 5% of CBT recipients,
respectively (Supplementary Table S1).
GRFS
GVHD and relapse-free survival (GRFS) is increasingly recog-
nized as amajor endpoint in allo-HCT (30, 32, 33). Two-yearGRFS
was 39% in CBT recipients, 37% in haplo patients, 29% in MSD
patients, and 23% only in MUD recipients (P ¼ 0.0002; Fig. 2).
Since proportionality assumption was signiﬁcantly violated when
studyingGRFS (due to a higher incidence of grade III–IV acute but a
lower incidenceof severe chronicGVHD inCBT recipients),we split
the follow-up at day 100 (before and after the potential occurrence
of classical acuteGVHD). In comparisonwithMSD,CBTbeforeday
100 was associated with worse GRFS. However, after day 100, CBT
was associated with a signiﬁcantly better GRFS. In contrast, MUD
was associated with a signiﬁcantly worse GRFS (Table 3). Other
factors associated withworse GRFS inmultivariate analyses includ-
ed intermediate (HR¼ 1.4; 95%CI, 1.0–1.9; P¼ 0.03) and adverse
(HR ¼ 2.1; 95% CI, 1.5–2.9; P < 0.001) risk cytogenetics, and
female donor to male recipient (HR ¼ 1.2; 95% CI, 1.0–1.5; P ¼
0.03). In contrast, more recent transplantation was associated with
better GRFS (HR ¼ 0.98; 95% CI, 0.95–0.99; P ¼ 0.047).
Discussion
Recent progress in haplo-HCT has changed the algorithm of
donor selection in many transplantation centers (34, 35). Con-
sequently, haplo-HCT is increasingly used in Europewhile the use
of CBT is declining (36). Several recent studies assessing the
impact of donor type on transplantation outcomes have been
reported (19, 24, 37–44). Limitation of these studies include the
use of conditioning regimens of various intensities, inclusion of
patients with various diagnoses, and/or relatively low number of
patients (19, 24, 37–44). Here, we assessed the impact of donor
type on transplantation outcomes in a large cohort of AML
patients transplanted with a low-dose TBI-based nonmyeloabla-
tive regimen. Several observations were made.
A ﬁrst observation was that the relapse incidence was compa-
rable between MSD, MUD, haplo, and CBT patients. As nonmye-
loablative allo-HCT relies nearly exclusively on GvL effects
for tumor eradication, our data suggest that the magnitude of
GvL effects is comparable with these different approaches,
although some caution should be given for the haplo group given
the relatively low number of patients in that group and their
relatively short follow-up. Also one cannot exclude that the higher
doses of ﬂudarabine (and additional Cy) given to secure engraft-
ment in CBT and haplo patients might have provided a little
additional antileukemic effects. Previous studies using various
conditioning regimens also observed a comparable risk of relapse
betweenMSD andMUD (20, 22, 43, 45),MSD and haplo (24, 39,
42), MUD and haplo (43, 44), MUD and CBT (37), and between
CBT and haplo (38). In contrast, another study observed a
higher risk of relapse in haplo than in MUD in the setting of
reduced-intensity conditioning (40). It is possible that posttrans-
plant Cy administered in all haplo patients impacted GvL effects.
Unfortunately, the number of MSD/MUD patients given
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A, Acute (a) GVHD, chronic (c) GVHD
and NRM according to donor type. B,
Relapse incidence, LFS, and OS
according to donor type.
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posttransplant Cy in our cohort was too low to assess its impact of
GvL effects in that group of patients.
Importantly, OS and LFS were comparable with the 4 donor
types, although there was a suggestion for lower OS with haplo
than with MSD. Looking at causes of death, we observed a
trend for higher infection-related mortality in haplo recipients
than in patients given grafts from other donor types. Interest-
ingly, in contrast to the results reported by the BMT-CTN
network study comparing haplo (n ¼ 50) and CBT (n ¼ 50)
following ﬂudarabine þ 2 Gy TBI where 1-year NRM was 24%
with CBT and only 7% with haplo (19), we observe similar 2-
year NRM in CBT (16%) and haplo (22%) patients. Reasons
for these discrepancies are unclear but might be perhaps
explained by different underlying diseases (only AML in the
current study versus various diagnoses in the BMT-CTN study)
or by strict inclusion criteria in the BMT-CTN study while
current analyses report data from "real life" patients. There
was also perhaps a center effect (T-cell–repleted haplo is
rather a newer transplantation strategy in Europe) since center
(fraility) was signiﬁcantly associated with NRM in multivariate
analyses. Finally, another possible confounding factor is that,
while almost all MSD and MUD patients were given PBSC,
approximately half of the haplo patients received bone mar-
row as stem cell source. However, a recent study from our
group comparing PBSC with BM in non-T-cell depleted haplo
AML patients (given various conditioning regimen) observed
similar outcomes with the two stem cell sources, with the
exception of faster engraftment and higher incidence of GVHD
in PBSC patients (46).
Our study revealed a high incidence of grade III–IV acute
GVHD in CBT recipients (15%). A recent study from our group
observed that the low incidence of acute GVHD associated with
CBT is limited to CBT patients receiving ATG in the condition-
ing regimen (47). In concordance with this observation, the
incidence of grade III–IV acute GVHD in our study was similar
to what has been reported by the Seattle (18%; ref. 41) or the
Minesotta (19%; ref. 48) teams that used a similar ATG-free
nonmyeloablative HCT platform.
Table 2. Multivariate analyses for GVHD
Acute GVHD II–IV Acute GVHD III–IV Chronic GVHD Extensive chronic GVHD
HR (CI) P HR (CI) P HR (CI) P HR (CI) P
MSD (reference) 1.0 1.0 1.0 1.0
MUD 10/10 1.9 (1.4–2.7) <0.001 0.9 (0.5–1.8) 0.76 1.3 (1.0–1.7) 0.04 1.6 (1.2–2.3) 0.005
Haplo 1.5 (0.9–2.7) 0.14 1.1 (0.4–2.9) 0.92 0.7 (0.4–1.2) 0.19 0.5 (0.2–1.3) 0.14
CBT 2.9 (2.0–4.4) <0.001 2.9 (1.5–5.6) 0.001 0.4 (0.3–0.6) <0.001 0.3 (0.2–0.5) <0.001
CR2 vs. CR1 0.8 (0.5–1.1) 0.10 0.6 (0.3–1.1) 0.08 1.1 (0.8–1.4) 0.57 1.1 (0.7–1.6) 0.69
Age (per 10y) 1.1 (1.0–1.2) 0.14 1.1 (0.9–1.4) 0.33 1.0 (0.9–1.1) 0.94 1.0 (0.8–1.1) 0.63
Year of Tx 1.0 (1.0–1.0) 0.91 1.0 (0.9–1.1) 0.88 1.0 (0.9–1.0) 0.09 0.9 (0.9–1.0) 0.003
Good risk (reference) 1.0 1.0 1.0 1.0
Intermediate risk 1.4 (0.8–2.4) 0.30 1.2 (0.5–3.1) 0.72 1.0 (0.7–1.4) 0.79 1.2 (0.7–2.0) 0.56
Adverse risk 1.5 (0.8–2.8) 0.23 0.8 (0.3–2.5) 0.75 0.9 (0.6–1.5) 0.77 1.3 (0.7–2.4) 0.42
Sec. AML 0.7 (0.5–1.1) 0.14 1.0 (0.5–2.0) 0.91 0.8 (0.6–1.2) 0.26 0.8 (0.5–1.3) 0.42
Female D to male vs. other 1.3 (0.9–1.7) 0.17 1.1 (0.6–1.9) 0.78 1.4 (1.1–1.7) 0.01 1.6 (1.2–2.2) 0.003
Patient CMV positive 0.8 (0.6–1.1) 0.22 1.1 (0.7–1.8) 0.68 1.0 (0.8–1.3) 0.78 1.1 (0.8–1.5) 0.38
Donor CMV positive 1.1 (0.9–1.5) 0.37 0.9 (0.6–1.5) 0.76 1.2 (1.0–1.4) 0.13 1.2 (0.9–1.6) 0.15
Centre (frailty) 0.007 0.03 0.24 0.01
Abbreviations: 10y, 10 years; CBT, cord blood transplant recipients; CR, complete remission; Haplo,MSD, HLA-matched sibling donor; MUD 10/10, 10/10 HLA-matched
unrelated donor; sec AML, secondary AML; Tx, transplantation.
Table 3. Multivariate analyses for relapse, NRM, and GRFS (nonproportionality for donor type before and after day 100)
Relapse NRM GRFS
HR (CI) P HR (CI) P HR (CI) P
MSD (reference) 1.0 1.0 1.0
MUD 10/10 within 100 days 0.9 (0.7–1.2) 0.55 2.3 (1.6–3.4) <0.001 1.1 (0.8–1.6) 0.50
MUD 10/10 after 100 days 0.9 (0.6–1.2) 0.42 2.5 (1.7–3.7) <0.001 1.3 (1.1–1.7) 0.001
Haplo within 100 days 1.0 (0.6–1.6) 0.95 2.4 (1.2–4.9) 0.01 1.4 (0.8–2.3) 0.21
Haplo after 100 days 1.2 (0.7–2.2) 0.42 1.3 (0.5–3.5) 0.63 0.7 (0.5–1.1) 0.16
CBT within 100 days 1.1 (0.8–1.4) 0.74 1.8 (1.1–2.9) 0.02 1.6 (1.1–2.2) 0.01
CBT after 100 days 1.3 (0.9–1.8) 0.19 1.0 (0.5–1.8) 0.89 0.6 (0.5–0.8) 0.002
CR2 vs. CR1 1.2 (1.0–1.5) 0.1 0.9 (0.6–1.2) 0.40 1.0 (0.8–1.2) 0.95
Age (per 10y) 0.9 (0.9–1.0) 0.08 1.4 (1.2–1.6) <0.001 1.0 (0.9–1.1) 0.61
Year of Tx 1.0 (1.0–1.0) 0.88 1.0 (0.9–1.0) 0.08 1.0 (1.0–1.0) 0.047
Good risk (reference) 1.0 1.0 1.0
Intermediate risk 1.5 (1.0–2.1) 0.04 1.0 (0.7–1.7) 0.84 1.4 (1.0–2.0) 0.03
Adverse 3.4 (2.3–5.1) <0.001 0.9 (0.5–1.6) 0.80 2.1 (1.5–2.9) <0.001
Sec. AML 1.0 (0.8–1.4) 0.78 1.2 (0.8–1.8) 0.26 1.0 (0.8–1.3) 0.88
Female D to male vs. other 0.7 (0.6–0.9) 0.02 1.7 (1.3–2.3) <0.001 1.2 (1.0–1.5) 0.03
Patient CMV positive 0.9 (0.7–1.1) 0.22 1.1 (0.8–1.4) 0.46 1.1 (0.9–1.3) 0.28
Donor CMV positive 1.3 (1.1–1.5) 0.01 1.0 (0.8–1.3) 0.91 1.1 (1.0–1.3) 0.10
Centre (frailty) 0.11 <0.001 0.27
Abbreviations: 10y, 10 years; CBT, cord blood transplant recipients; CR, complete remission; MSD, HLA-matched sibling donor; MUD 10/10, 10/10 HLA-matched
unrelated donor; sec AML, secondary AML; Tx, transplantation.
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GRFS is increasingly recognized as a major endpoint in allo-
HCT (30). Interestingly, while the number of CBT performed in
Europe for AML is declining, our study observed a better GRFS
beyond day 100 in CBT recipients than in MSD. This was due to a
relatively low incidence of relapse in CBT recipients in the context
of very low incidence of chronic GVHD. Interestingly, as reported
previously (26), GRFS was comparable in single or double CBT
recipients (Supplementary Table S2). Similarly, haplo patients
had also an encouragingGRFS (no statistically different thanCBT)
due to a low incidence of chronic GVHD. In contrast, MUD
recipients had a relatively low GRFS due to a high incidence of
both grade III–IV acute and chronic GVHD. Although GRFS is a
new important endpoint in allo-HCT as it might better reﬂect
health status and quality of live than LFS, it has also some
limitation and should not be used alone for decision making.
Indeed, chronic GVHD grading has remained somewhat observer
dependent, and patients with severe chronic GVHD can achieve a
good quality of life after GVHD resolution.
Main causes of death following this low-intensity condi-
tioning regimen consisted of disease relapse, infections and
GVHD. Approaches to decrease the incidence of disease relapse
might consist of increasing the intensity of the conditioning
regimen (for example with the addition of treosulfan (49) or
with radiolabeled antibodies (50, 51)) or adding disease-
targeted therapies after transplantation (52, 53). Furthermore,
recent studies have demonstrated that triple postgrafting
immunosuppression with cyclosporine, MMF and sirolimus
improved outcomes in MUD patients conditioned with
ﬂudarabine þ 2 Gy TBI (54), while administration MMF at
the dose of 3g/day (instead of 2 g/day) decreased the incidence
of grade II–IV acute GVHD without affecting infection-related
mortality of other transplantation outcomes in the double
CBT setting (55).
There are some limitations in the study including missing
data on comorbidity (56) other than Karnofsky score, min-
imal residual disease (57), and cytogenetic/molecular abnor-
malities in many patients. In addition, the very low number
of MSD and MUD patients receiving posttransplant Cy as
GVHD prophylaxis precluded us to add this potentially
confounding factor in the multivariate Cox analyses. Another
limitation inherent to registry study is that we do not have
data on some pretransplant relevant events such as time to
ﬁnd the donor, additional cycles of chemotherapy, or early
relapses that might have eliminated some of the more
aggressive leukemia from the alternative donor transplant
groups. Indeed, these latter were associated with a longer
interval from diagnosis to transplantation (in CR1 patients)
in comparison with MSD patients. However, this study is the
largest one thus far comparing the impact of donor type in
AML patients given grafts after ﬂudarabine – 2 Gy TBI
conditioning.
Conclusions
In this large cohort of AML patients transplanted in CR fol-
lowing low-dose TBI-based nonmyeloablative conditioning reg-
imen, the relapse incidence was not affected by donor type
suggesting that the intensity of GVL effects is comparable with
these four transplant approaches. Furthermore, MUD patients
had lowerGRFS thanMSDpatientswhileCBTwas associatedwith
a better GRFS than MSD beyond day 100 suggesting that CBT
remains a valid transplantation approach with this low-intensity
conditioning regimen.
Table 4. Multivariate analyses for LFS and OS
LFS OS
HR (CI) P HR (CI) P
MSD (reference) 1 1
MUD 10/10 1.1 (0.9–1.5) 0.35 1.2 (0.9–1.6) 0.18
Haplo 1.3 (0.9–2.0) 0.16 1.4 (0.9–2.2) 0.09
CBT 1.2 (0.9–1.5) 0.3 1.1 (0.8–1.5) 0.39
CR2 vs. CR1 1.2 (0.9–1.5) 0.22 1.1 (0.8–1.5) 0.45
Age (per 10y) 1 (0.9–1.1) 0.51 1 (0.9–1.1) 0.43
Year of Tx 1 (1.0–1.0) 0.58 1 (0.9–1.0) 0.89
Good risk (reference) 1 1
Intermediate risk 1.6 (1.0–2.4) 0.04 1.9 (1.2–3.1) 0.01
Adverse risk 2.9 (1.8–4.5) <0.001 3.4 (2.0–5.7) <0.001
Sec. AML 1.3 (1.0–1.7) 0.06 1.4 (1.0–1.8) 0.04
Female D to male vs. other 0.9 (0.7–1.1) 0.37 1 (0.7–1.2) 0.74
Patient CMV positive 1 (0.8–1.2) 0.88 1.1 (0.9–1.3) 0.48
Donor CMV positive 1.1 (0.9–1.4) 0.16 1.1 (0.8–1.3) 0.43
Centre (frailty) 0.25 0.18
Abbreviations: 10y, 10 years; CBT, cord blood transplant recipients; CR, complete remission; MSD, HLA-matched sibling donor; MUD 10/10, 10/10 HLA-matched
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List of institutions
The EBMT registry is a voluntary working group of more than
500 transplant centers, participants of which are required once a
year to report all consecutive stem cell transplantations and
follow-up. The list of institutions reporting data included in this
study is provided in the Supplementary Data.
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